Enhanced systemic availability of methotrexate in the presence of morin in rats

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 4, 2008, Pages 189-193

  Hong, Soon Sun ^a   Jin, Ming Ji ^b   Han, Hyo Kyung ^b  

^a Inha University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Morin; MTX; Pharmacokinetics; Rats; Renal excretion

Indexed keywords

METHOTREXATE; MORIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG UPTAKE; KIDNEY CLEARANCE; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA HALF LIFE; PROTEIN EXPRESSION; RAT; URINARY EXCRETION;

ANIMALS; FLAVONOIDS; FOLIC ACID ANTAGONISTS; INJECTIONS, INTRAVENOUS; MALE; METHOTREXATE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 44949218435     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.602     Document Type: Article

References (29)

1. Djerassi I. Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report. Cancer Res 1967; 27: 2561-2564.
2. Levitt M, Mosher MB, DeConti RC, et al. Improved therapeutic index of methotrexate with 'leucovorin rescue'. Cancer Res 1973; 33: 1729-1734.
3. Frei E 3rd, Jaffe N, Tattersall MH, Pitman S, Parker L. 1975. New approaches to cancer chemotherapy with methotrexate. N Engl J Med 1975; 292: 846-851.
4. Chladek J, Grim J, Martinkova J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54: 147-156.
5. Burchini G, Orsi C. Rheumatoid arthritis. N Engl J Med 2004; 351: 1360-1361.
6. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986; 1: 1390.
7. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986; 1: 256-258.
8. Bourke RS, Chheda G, Bremer A, Watanabe O, Tower DB. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975; 35: 110-116.
9. Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978; 1: 1097-1099.
10. Chiang HM, Fang SH, Wen KC, et al. Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats. Toxicol Appl Pharmacol 2005; 209: 263-268.
11. Cassileth BR, Deng G. Complementary and alternative therapies for cancer. Oncologist 2004; 9: 80-89.
12. Richardson MA, Straus SE. Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin Oncol 2002; 29: 531-545.
13. Wu TW, Zeng LH, Wu J, Fung KP. Morin: a wood pigment that protects three types of human cells in the cardiovascular system against oxyradical damage. Biochem Pharmacol 1994; 47: 1099-1103.
14. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anion. Biochem Pharmacol 1988; 37: 83-88.
15. Stavric B. Role of chemopreventers in human diet. Clin Biochem 1994; 27: 319-332.
16. Choi BC, Choi JS, Han HK. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharm 2006; 323: 81-85.
17. Choi JS, Han HK. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol Res 2005; 52: 386-391.
18. Wang Q, Morris ME. Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos 2007; 35: 201-208.
19. Hong SS, Seo K, Lim SC, Han HK. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol Res 2007; in press.
20. Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002; 302: 666-671.
21. Aslamkhan AG, Han YH, Yang XP, Zalups RK, Pritchard JB. Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin-Darby canine kidney cells. Mol Pharmacol 2003; 63: 590-596.
22. Ueda K, Kato Y, Komatsu K, Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: Quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 2001; 297: 1036-1043.
23. Kuroda T, Namba K, Torimaru T, Kawashima K, Hayashi M. Species differences in oral bioavailability of methotrexate between rats and monkeys. Biol Pharm Bull 2000; 23: 334-338.
24. Uwai Y, Taniquchi R, Motohashi H, Saito H, Okuda M, Inui KI. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet 2004; 19: 369-374.
25. Kwak JO, Kim HW, Oh KJ, Kim DS, Han KO, Cha SH. Colocalization and interaction of organic anion transporter 1 with caveolin-2 in rat kidney. Exp Mol Med 2005; 37: 204-212.
26. Iven H, Brasch H. Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemother Pharmacol 1986; 17: 218-222.
27. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61: 7225-7232.
28. Gifford AJ, Kavallaris M, Madafiglio J, et al. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer 1998; 78: 176-181.
29. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006; 78: 2116-2130.